Bye-bye, build-to-buy

Why Versant is moving away from the build-to-buy model

As another Inception Sciences Inc. company secures an exit, Versant Ventures plans to move away from its build-to-buy model to focus on creating stand-alone companies with broader portfolios and investor syndicates.

On Oct. 31, Ophthotech Corp. (NASDAQ:OPHT) acquired Inception 4 Inc., gaining small molecule inhibitors of HtrA serine peptidase 1 (HTRA1) to treat age-related retinal

Read the full 554 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers